Me-4FDG PET/CT Scan for Lung Cancer
Recruiting in Palo Alto (17 mi)
+1 other location
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 1 & 2
Recruiting
Sponsor: Jonsson Comprehensive Cancer Center
Must not be taking: SGLT2 inhibitors, Metformin
Disqualifiers: Pregnancy, Diabetes
No Placebo Group
Trial Summary
What is the purpose of this trial?The phase I/II trial assess the safety and efficacy of a new positron emission tomography (PET) test for early diagnosis of lung cancer. This study uses PET and Me-4FDG new glucose tracer (alpha-methyl-4-deoxy-4-\[(18)F\]fluoro-D-glucopyranoside) designed specifically to determine glucose update into cells in the body. PET is a non-invasive imaging method used to detect cancer in patient. Me4FDG is a radioactive glucose tracer used in PET to locate cells in the body taking up glucose by SGLT2. SLGT2 is a sodium glucose transport protein that accumulates glucose in some cells, e.g. kidney cells and tumors. This study may help researcher determine how effective PET with ME4FDG tracer works in detecting lung cancer.
Will I have to stop taking my current medications?
If you are currently taking SGLT2 inhibitors or metformin, you will need to stop these medications to participate in the trial.
Is Me-4FDG PET/CT Scan for Lung Cancer safe for humans?
There is a report of an allergic reaction, including low blood pressure, after using a similar tracer, [(18)F]FDG, which is used in PET scans. This suggests that while generally considered safe, there may be rare cases of allergic reactions.
12345How is the drug Me-4FDG different from other treatments for lung cancer?
Me-4FDG is a novel imaging agent used in PET/CT scans for lung cancer, designed to selectively accumulate in malignant tissues, potentially offering more specific tumor detection compared to the commonly used FDG, which can also accumulate in non-cancerous conditions.
678910Eligibility Criteria
This trial is for adults over 18 with lung nodules seen on CT scans. It's open to those with confirmed lung adenocarcinoma and also to those with nodules considered benign. People can't join if they're taking diabetes medications like SGLT2 inhibitors or metformin, have a diabetes diagnosis, or are pregnant.Inclusion Criteria
My lung nodules are considered benign with a lung-RADS score of 1-3.
My lung cancer is confirmed to be adenocarcinoma.
You have a lung spot that is at least 1 cm in size seen on a CT scan.
+1 more
Exclusion Criteria
I am currently taking SGLT2 inhibitors or metformin.
I have been diagnosed with diabetes.
Pregnancy
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
2-4 weeks
Treatment
Participants receive Me-4FDG tracer intravenously and undergo PET/CT over 15 minutes
1 day
1 visit (in-person)
Follow-up
Participants are monitored for safety and effectiveness after treatment
1 week
1 visit (in-person)
Participant Groups
The study tests a new PET scan using Me-4FDG, a radioactive glucose tracer that helps detect cancer by showing where glucose is absorbed in the body. The goal is to see how well this new method works for early detection of lung cancer compared to current techniques.
1Treatment groups
Experimental Treatment
Group I: Diagnostic (Me-4FDG PET/CT)Experimental Treatment4 Interventions
Patients receive Me-4FDG tracer IV and then undergo PET/CT over 15 minutes.
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
UCLA / Jonsson Comprehensive Cancer CenterLos Angeles, CA
Yesenia CalzadaLos Angeles, CA
Loading ...
Who Is Running the Clinical Trial?
Jonsson Comprehensive Cancer CenterLead Sponsor
Lungevity FoundationCollaborator
LUNGevity FoundationCollaborator
American Cancer Society, Inc.Collaborator
References
In vitro and in vivo characterization of 2-deoxy-2-18F-fluoro-D-mannose as a tumor-imaging agent for PET. [2016]2-Deoxy-2-(18)F-fluoro-d-mannose ((18)F-FDM) is an (18)F-labeled mannose derivative and a stereoisomer of (18)F-FDG. Our preliminary study demonstrated that (18)F-FDM accumulated in tumors to the same extent as (18)F-FDG, with less uptake in the brain and faster clearance from the blood. However, detailed studies on the uptake of (18)F-FDM in tumors have not been conducted. We undertook this study to establish a practical method of (18)F-FDM synthesis based on an (18)F-nucleophilic substitution (SN2) reaction and to advance the biologic characterization of (18)F-FDM for potential application as a tumor-imaging agent.
The synthesis of 18F-FDS and its potential application in molecular imaging. [2021]2-deoxy-2-[(18)F]fluoro-D-glucose (FDG) is the most commonly used positron emission tomography (PET) tracer for oncological and neurological imaging, but it has limitations on detecting tumor or inflammation in brain gray matter. In this study, we describe the development of 2-deoxy-2-[(18)F]fluorosorbitol ((18)F-FDS) and its possible application in lesion detection around brain area.
An unusual case of anaphylaxis after fluorine-18-labeled fluorodeoxyglucose injection. [2021][(18)F]FDG (fluorine-18 fluoro-2-deoxy-D-glucose) positron emission tomography (PET) is used worldwide for oncologic and neurologic applications. To date, the potential harm caused by [(18)F]FDG has focused on its radiation exposure effects rather than on its pharmacological effects. While an allergic response in the form of a skin manifestation has been reported after exposure to [(18)F]FDG, this report describes the first case of hypotension following exposure to this tracer. Here, the development of anaphylaxis after [(18)F]FDG injection is described.
Synthesis and biodistribution of 2-deoxy-2-[18F]fluoro-D-glucopyranosyl [18F]fluoride in mice. [2019]The synthesis and biodistribution of 2-deoxy-2-[18F]fluoro-D-glucopyranosyl [18F]fluoride (4 approximately) in mice are described. Reaction of 3,4,6-tri-O-acetyl-D-glucal (1 approximately) with [18F]F2 in freon-11 at -78 degrees C gives 2-deoxy-2-[18F]fluoro-3,4,6-tri-O-acetyl-alpha-D-glucopyranosyl [18F]fluoride (2 approximately) and 2-deoxy-2-[18F]fluoro-3,4,6-tri-O-acetyl-beta-D-mannopyranosyl [18F]fluoride (3 approximately). Partial hydrolysis of 2 approximately with NaOMe/MeOH gives compound 4 approximately in a radiochemical yield of approximately 28% (based on 18F recovered) and in a synthesis time of 70 min from EOB. The biodistribution of compound 4 approximately in mice suggests that it defluorinates in vivo to give 2-deoxy-2-[18F]fluoro-D-glucose (5 approximately) and [18F]fluoride as metabolites.
Imaging of canine cancers with 18F-2-fluoro-2-deoxy-D-glucose (FDG) suggests further applications for cancer imaging in man. [2019]18F-2-fluoro-2-deoxy-D-glucose (FDG) is a novel radiopharmaceutical that has gained much interest as a cancer-seeking agent. In this paper two cases of histologically verified canine cancer, an osteosarcoma and a mammary carcinoma, are presented. After an intravenous bolus injection of FDG, accumulation of radioactivity over the neoplastic lesion was followed with a computer-guided specially collimated gamma camera. Ratios of radioactivity between tumour and control areas at 30 min were 2.8 and 2.2 for the osteosarcoma and the mammary carcinoma, respectively. In the osteosarcoma, which was imaged for 3 h, this ratio remained essentially stable. It is reasonable to assume that FDG will be suitable for cancer imaging in man.
State-of-the-Art FDG-PET imaging of lung cancer. [2019]The D-glucose analog 2-(fluorine-18)-fluoro-2-deoxy-D-glucose (FDG) is the most commonly used radionuclide in positron emission tomography (PET) of lung cancer. FDG-PET is a molecular imaging technique that images the preferential accumulation of FDG in malignant tissues with increased metabolism. Although FDG-PET is sensitive in the detection of lung cancer, FDG is not tumor specific and may accumulate in a variety of nonmalignant conditions. Occasional false-negative results may also occur. Whole body FDG-PET is a useful noninvasive technique to stage known or suspected non-small-cell lung cancer. The results allow more efficient use of invasive methods for histopathological staging. The combined use of CT and PET in dual imaging increases the number of patients with correctly staged non-small-cell lung cancer. CT/PET is also useful in the assessment of recurrent or residual disease. Future imaging agents are being developed which may allow more selective accumulation of radiopharmaceutical in malignant tissues.
Present and future roles of FDG-PET/CT imaging in the management of lung cancer. [2018]Integrated positron emission tomography/computed tomography (PET/CT) using 2-[(18)F]fluoro-2-deoxy-D-glucose ((18)F-FDG) has emerged as a powerful tool for combined metabolic and anatomic evaluation in clinical oncologic imaging. This review discusses the utility of (18)F-FDG PET/CT as a tool for managing patients with lung cancer. We discuss different patient management stages, including diagnosis, initial staging, therapy planning, early treatment response assessment, re-staging, and prognosis.
Positron emission tomography imaging in lung cancer. [2019]Over the past several years, positron emission tomography (PET) has become a clinically useful, noninvasive study which complements conventional imaging (chest radiographs, computed tomography [CT], and magnetic resonance imaging [MRI]) in the evaluation of patients with lung cancer. PET imaging of lung cancer is typically performed with the radiopharmaceutical 18F-2-deoxy-D-glucose (FDG), a d-glucose analog. Increased glucose metabolism by malignant cells results in increased uptake and accumulation of FDG, which serves as the basis for tumor detection. This review will focus on the current applications of FDG-PET in lung cancer patients including evaluation of focal pulmonary abnormalities, staging lung cancer, determining tumor recurrence, and in assessing prognosis.
The role of positron emission tomography with 18F-fluoro-2-deoxy-D-glucose in respiratory oncology. [2019]In the past 5 yrs, positron emission tomography (PET) with 18F-fluoro-2-deoxy-D-glucose (FDG) has become an important imaging modality in lung cancer patients. At this time, the indication of FDG-PET as a complimentary tool to computed tomography in the diagnosis and staging of nonsmall cell lung cancer has gradually gained more widespread acceptance and also reimbursement in many European countries. This review focuses on the data of FDG-PET in the diagnosis of lung nodules and masses, and in locoregional and extrathoracic staging of nonsmall cell lung cancer. Emphasis is put on the potential clinical implementation of the currently available FDG-PET data. The use of FDG-PET in these indications now needs further validation in large-scale multicentre randomized studies, focusing mainly on treatment outcome parameters, survival and cost-efficacy. Interesting findings with 18F-fluoro-2-deoxy-D-glucose-positron emission tomography have also been reported for the evaluation of response to radio- or chemotherapy, in radiotherapy planning, recurrence detection and assessment of prognosis. Finally, a whole new field of application of positron emission tomography in molecular biology, using new radiopharmaceuticals, is under extensive investigation.
[Value of Pet-18FDG in lung cancer]. [2016]18FDG-PET was studied in the diagnosis of malignancy of the solitary pulmonary nodule and in the early staging of non-small-cell lung cancer. PET results were compared with thoracic-abdominal computed tomography (CT) and brain magnetic resonance (MR).